Close
  Indian J Med Microbiol
 

Figure 1: IL-23A expression correlated with disease progression. (a) Comparison of IL-23A expression according to pT stage in the TCGA-PRAD cohort. Data are shown as the mean±s.d. and were compared with ANOVA. (b) Association of IL-23+ cells with GS subgroups. Data are shown as the mean±s.d. and were compared with ANOVA. Kaplan–Meier plots for (c) overall survival and (d) CRPC-free survival in the TCGA-PRAD cohort according to IL-23A expression. Sixteen cases without CRPC-free survival time were excluded in d. IL-23: interleukin-23; GS: Gleason score; TCGA-PRAD: The Cancer Genome Atlas prostate adenocarcinoma; ANOVA: analysis of variance; CRPC: castration-resistant prostate cancer; s.d.: standard deviation; FPKM: fragments per kilobase of exon per million fragments mapped.

Figure 1: IL-23A expression correlated with disease progression. (<b>a</b>) Comparison of IL-23A expression according to pT stage in the TCGA-PRAD cohort. Data are shown as the mean±s.d. and were compared with ANOVA. (<b>b</b>) Association of IL-23<sup>+</sup> cells with GS subgroups. Data are shown as the mean±s.d. and were compared with ANOVA. Kaplan–Meier plots for (<b>c</b>) overall survival and (<b>d</b>) CRPC-free survival in the TCGA-PRAD cohort according to IL-23A expression. Sixteen cases without CRPC-free survival time were excluded in <b>d</b>. IL-23: interleukin-23; GS: Gleason score; TCGA-PRAD: The Cancer Genome Atlas prostate adenocarcinoma; ANOVA: analysis of variance; CRPC: castration-resistant prostate cancer; s.d.: standard deviation; FPKM: fragments per kilobase of exon per million fragments mapped.